Therefore, in future clinical trials, this method should be first applied to BMMSCs or UCMSCs, more commonly used in trials, and compare the response rate and survival rate of GVHD patients to MSCs supplemented with albumin and FBS directly. Here, ALB is linked to graft versus host disease.